Revapta 0.5 is Registered Trademark of Company Medigen Life Sciences.
Product Description: Repaglinide Tablets USP 0.5 mg
Generic Name: Repaglinide
Strength: 0.5 mg
Dosage Form: Oral Tablet
Route of Administration: Oral
Packaging: { 10x1x10 }
Revapta (Repaglinide Tablets 0.5 mg)
Repaglinide is an oral antidiabetic agent used to manage Type 2 Diabetes Mellitus. It stimulates rapid, short-acting insulin release from the pancreas, helping control postprandial blood glucose levels. Taken before meals, Repaglinide offers flexible dosing and reduced risk of prolonged hypoglycemia.